Zimmer Biomet Transitions to New Chief Financial Officer Amid Organizational Changes

Zimmer Biomet Announces New CFO Appointment

Warsaw, Indiana – April 28, 2026 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) has recently made significant leadership changes in its financial department. Effective April 28, Suketu Upadhyay will leave his position as Chief Financial Officer (CFO) and Executive Vice President of Finance, Operations, and Supply Chain to pursue a new professional venture.

In light of this transition, the company has appointed Paul Stellato, currently serving as Controller and Chief Accounting Officer, to take on the role of interim CFO. This appointment is part of the company’s strategy to ensure consistency and stability during the leadership change. Ivan Tornos, Chairman, President, and CEO of Zimmer Biomet expressed his gratitude for Upadhyay’s contributions during his seven-year tenure with the company.

Paul Stellato's Background

Paul Stellato is no stranger to financial leadership within Zimmer Biomet, having joined the company in May 2022. He possesses over 20 years of extensive experience in financial management and investor relations. Stellato's previous roles at Xylem Inc. included Vice President of Finance for Global Business Services and responsibilities as Vice President, Controller, and Chief Accounting Officer. His wealth of experience encompasses various finance-related roles, fostering advanced capital allocation strategies, including notable acquisitions and a dynamic share repurchase program.

Before his successful stint at Xylem, Stellato honed his financial skills at ITT Corporation, where he held diverse roles of increasing responsibility. He began his career in public accounting with prestigious firms, Andersen and Ernst & Young. His educational credentials include a Bachelor of Science in Accountancy from Villanova University and an MBA from New York University's Stern School of Business, along with certification as a public accountant.

Strategic Direction During Transition

As Zimmer Biomet embarks on the search for a permanent CFO, Stellato's interim leadership is expected to guide the company through a crucial transitional phase. He has committed to maintaining corporate strategy continuity, focusing on delivering on commitments to stakeholders while upholding the company’s mission to enhance patient mobility and health through innovative solutions.

Zimmer Biomet, with its legacy of over 90 years in the medical technology sector, emphasizes a commitment to innovation and excellence in patient care. The company continues to leverage advanced data analytics and AI technologies to boost the efficacy of its extensive product portfolio. As they navigate this leadership transition, Zimmer Biomet’s steadfast vision remains clear: to offer the highest quality solutions to patients and healthcare providers around the globe.

Looking Ahead

This leadership transition comes at a time when Zimmer Biomet is poised for further growth and innovation within the medical technology arena. The incoming interim CFO, Stellato, highlighted his eagerness to build upon the strong foundation established by his predecessor and continue driving the company forward. As the search for a permanent CFO unfolds, the company remains optimistic about its financial future and its ongoing mission to make a difference in patients' lives worldwide.

For further details regarding Zimmer Biomet's products and corporate strategies or to explore opportunities within their team, please visit Zimmer Biomet’s website or connect with them on LinkedIn and X to stay updated on the latest developments.

In conclusion, while the departure of Suketu Upadhyay marks a significant change within the team, the appointment of Paul Stellato exemplifies the commitment to ensuring a smooth transition as Zimmer Biomet continues to thrive in the global medical technology landscape.